275 related articles for article (PubMed ID: 10666369)
1. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.
Chan WY; Cheung KK; Schorge JO; Huang LW; Welch WR; Bell DA; Berkowitz RS; Mok SC
Am J Pathol; 2000 Feb; 156(2):409-17. PubMed ID: 10666369
[TBL] [Abstract][Full Text] [Related]
2. Significance of apoptosis related proteins on malignant transformation of ovarian tumors: A comparison between Bcl-2/Bax ratio and p53 immunoreactivity.
Zeren T; Inan S; Vatansever HS; Sayhan S
Acta Histochem; 2014 Oct; 116(8):1251-8. PubMed ID: 25108507
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma.
Sato S; Kigawa J; Minagawa Y; Okada M; Shimada M; Takahashi M; Kamazawa S; Terakawa N
Cancer; 1999 Oct; 86(7):1307-13. PubMed ID: 10506718
[TBL] [Abstract][Full Text] [Related]
4. [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis].
Han XY; Chen Y; Hou MM; Zhang J; Yang KX; Chen YY; Qie MR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 39(4):619-22, 634. PubMed ID: 18798508
[TBL] [Abstract][Full Text] [Related]
5. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
6. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
7. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters.
Arik D; Kulaçoğlu S
Turk Patoloji Derg; 2011 Jan; 27(1):38-45. PubMed ID: 21469425
[TBL] [Abstract][Full Text] [Related]
8. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis and apoptosis-related proteins in the epithelium of human ovarian tumors: immunohistochemical and morphometric studies.
Ben-Hur H; Gurevich P; Huszar M; Ben-Arie A; Berman V; Tendler Y; Tchanishev R; Zinder O; Mor G; Zaltsman Y; Kohen F; Zusman I
Eur J Gynaecol Oncol; 1999; 20(4):249-53. PubMed ID: 10475115
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis in epithelial ovarian tumours Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax).
de la Torre FJ; García A; Gil-Moreno A; Planaguma J; Reventos J; Ramón y Cajal S; Xercavins J
Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):121-8. PubMed ID: 16876311
[TBL] [Abstract][Full Text] [Related]
12. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy.
Birner P; Schindl M; Obermair A; Breitenecker G; Oberhuber G
Clin Cancer Res; 2001 Jun; 7(6):1661-8. PubMed ID: 11410504
[TBL] [Abstract][Full Text] [Related]
13. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
14. Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours.
Fauvet R; Poncelet C; Hugol D; Lavaur A; Feldmann G; Daraï E
Virchows Arch; 2003 Jul; 443(1):38-43. PubMed ID: 12756564
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic significance of Bcl-2 in ovarian tumours.
Henriksen R; Wilander E; Oberg K
Br J Cancer; 1995 Nov; 72(5):1324-9. PubMed ID: 7577491
[TBL] [Abstract][Full Text] [Related]
16. The immune system, apoptosis and apoptosis-related proteins in human ovarian tumors (a review).
Zusman I; Gurevich P; Gurevich E; Ben-Hur H
Int J Oncol; 2001 May; 18(5):965-72. PubMed ID: 11295042
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours.
Athanassiadou P; Petrakakou E; Sakelariou V; Zerva C; Liossi A; Michalas S; Athanassiades P
Eur J Cancer Prev; 1998 Jun; 7(3):225-31. PubMed ID: 9696931
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis in epithelial ovarian tumors.
Preethi TR; Chacko P; Kesari AL; Praseeda I; Chellam VG; Pillai MR
Pathol Res Pract; 2002; 198(4):273-80. PubMed ID: 12049336
[TBL] [Abstract][Full Text] [Related]
19. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.
Tomita Y; Bilim V; Kawasaki T; Takahashi K; Okan I; Magnusson KP; Wiman KG
Int J Cancer; 1996 May; 66(3):322-5. PubMed ID: 8621251
[TBL] [Abstract][Full Text] [Related]
20. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
